Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of Thiol Compounds to Treat Neurological Disease

a technology of neurological disease and thiol compounds, which is applied in the direction of heterocyclic compound active ingredients, drug compositions, nervous disorders, etc., can solve the problems of danger when not properly controlled, and achieve the effects of reducing calcium transport, improving cell viability, and relieving mitochondrial stress

Inactive Publication Date: 2019-01-31
MERCAPTOR DISCOVERIES INC
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent describes a compound that can reduce the buildup of harmful proteins in the brain associated with neurodegenerative diseases such as Alzheimer's. The compound can also improve cell health and reduce damage to the mitochondria (the energy-producing part of cells), as well as inhibit the activity of certain proteins involved in calcium transport. The compound has been found to reduce the levels of reactive oxidants in the brain, increase the levels of certain amino acids, and reduce interactions between metal ions and proteins. Overall, this compound has shown promise in protecting brain cells and reducing the symptoms associated with neurodegenerative diseases.

Problems solved by technology

As strong coordination ligands, they allow proteins to access metal ion chemistry, which are fundamental to the generation of energy and electron-rich cellular currencies but may be dangerous when not properly controlled (35-41).

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of Thiol Compounds to Treat Neurological Disease
  • Use of Thiol Compounds to Treat Neurological Disease
  • Use of Thiol Compounds to Treat Neurological Disease

Examples

Experimental program
Comparison scheme
Effect test

example 1

Oxidative Stress and its Prevention by Captons

[0207]While the assay with Q111 striatal neurons may measure the ability to rescue sulfur starvation, the previous assay does not measure rescue from excitotoxicity and the effects on neurotransmission and neuroprotection mediated by the small thiol compounds. The ability of test compounds to inhibit glutamate-induced excitotoxicity (neuroprotection) in St-HdhQ111 / 111 cells is determined by incubating the small thiol compounds with cells for 60 min at 33° C., 95% (v:v) air / 5% (v:v) CO2 in BrainPhys complete media (STEMCELL Technologies, Vancouver, British Columbia, Canada). Following this, excitotoxicity is induced by the addition of 0.5 mM L-glutamate for 24 hours. Cell viability is assessed by measuring ATP levels, e.g., using a luminescent-based CellTitre Glo assay (Promega). Compound neuroprotection (% cell survival) is expressed as a % of the effect recorded with 100 μM cysteamine (denoted as 100% cell survival).

[0208]It is expected...

example 2

ggregation and its Prevention by Captons

[0209]The ability of test compounds to diminish aggregate formation in cells treated with hydrogen peroxide is determined. Briefly, MyCell SOD1 (G93A) neurons (CDI, Madison, Wis.) are cultured in 95% (v:v) air / 5% (v:v) CO2 in BrainPhys complete media (STEMCELL Technologies). Excitotoxic stress is induced by the addition of 0.5 mM L-glutamate for 2 hours, with and without capton or controls. Cells are harvested, pelleted and snap frozen. Frozen whole-cell pellets are homogenized in lysis buffer (25 mM Tris, pH 7.8, supplemented with protease inhibitors) at 4° C. by brief sonication and cleared by centrifugation at 18,000×g. Soluble SOD1-containing cleared supernatants are snap frozen for later analysis. Insoluble SOD1 (aggregated) is extracted from the lysed cell pellet. Pellets are re-suspended in 1 mL washing buffer (50 mM Tris HCl pH 7.4, 100 mM NaCl, 10% glycerol (v:v), 1% Triton X-100 (v:v), 0.5% NP-40 (v:v) with protease inhibitors by vor...

example 3

of Glutamate-Induced Excitotoxic Stress and Modulation of GABA Pathways by Oxidized Captons (O-Captons)

[0211]MyCell SOD1 (G93A) neurons (CDI, Madison, Wis.) are plated at a density of 20,000 cells / well in 384-well format in BrainPhys medium (STEMCELL Technologies, Vancouver, British Columbia, Canada) with antioxidants, 1 μg / mL laminin and neuronal growth factor supplements. Pre-coated poly-D-lysine (PDL) plates are coated with matrigel as a matrix according to standard protocol. Half the medium is changed every 3 days for 3 weeks. Cells are treated with either glutamate receptor antagonists, GABA receptor agonists, GABA receptor antagonists, or VGCC blockers in the presence or absence of either captons or o-captons for 30 min. Cells are then dosed with glutamate at 500 μM. At various timepoints, cells are assayed for viability using CellTiter-Glo 2.0 or calcium content using a total intracellular calcium kit or ROS using appropriate, commercially-available test kits. Cells are on ot...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
aggregationaaaaaaaaaa
oxidative stressaaaaaaaaaa
Login to View More

Abstract

The present disclosure relates, in general, to use of small diffusible thiols in the treatment of neurodegenerative diseases associated with glutamate excitotoxicity, protein aggregation and oxidative stress in the central nervous system, particularly in the brain.

Description

FIELD OF THE DISCLOSURE[0001]The present disclosure relates, in general, to use of small diffusible thiols in the treatment of neurodegenerative diseases associated with glutamate excitotoxicity, protein aggregation and oxidative stress in the central nervous system, particularly in the brain.BACKGROUND[0002]Endogenous thiols, primarily cysteine and its derivatives, act as electron sources and transfer mediators, ensuring the homeostatic maintenance of organellar redox states, especially in the mitochondria (25-34). As strong coordination ligands, they allow proteins to access metal ion chemistry, which are fundamental to the generation of energy and electron-rich cellular currencies but may be dangerous when not properly controlled (35-41). It has been shown that upon ingestion, cysteamine or cystamine can increase levels of cysteine in blood by cleaving cystine (9-11). This effect, in turn, increases brain and intracellular sulfur amino acid levels by increasing flux through under...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/145A61K31/44A61K31/40A61K31/397A61P25/08
CPCA61K31/145A61K31/44A61K31/40A61K31/397A61P25/08A61K31/095A61K31/198A61K31/4035A61K31/404A61K31/407A61K31/415A61K31/445A61K31/506A61K31/167A61K31/5377A61P25/00
Inventor ZANKEL, TODD C.ISBELL, SARA LOUISE
Owner MERCAPTOR DISCOVERIES INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products